XCancer

Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy

Description:

To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy

Sponsor:

Peking University Cancer Hospital & Institute

Phase:

N/A

Contacts:

Yannan Yuan (CONTACT)

gcp_yuanyn@bjcancer.org

01088197730

Xiaoyi Guo, PhD (CONTACT)

15833916752@163.com

010-88196495

Government Study Link:

NCT06909604 - Click here to see study on

ClinicalTrials.gov

HER2-BCH

Isotope(s):
Target(s):
  • HER2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NOTA
Inclusion
  • Patients with HER2 positive or low tumors;
  • Receives neoadjuvant therapy
Exclusion
  • Significant hepatic or renal dysfunction;